Phaseline

Companies › Xentria

Xentria: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XTMAB-16–Phase 2Pulmonary Sarcoidosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06169397XTMAB-16Phase 2Pulmonary SarcoidosisImmunologyOct 2026
NCT05890729XTMAB-16Phase 1Pulmonary SarcoidosisImmunologyOct 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Restem Cellcolabs Clinical SPV EHL Bio Nature Cell Throne Biotechnologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.